Novo Nordisk A/S (NYSE: NVO) SHARES TUMBLED 20.57% TO $ 54.81 On Tuesday, Wiping Nearly $ 93billion from The Pharmaceutical Giant’s Market Value in One of ItS Steepest Single-Day Declines in Years.
This Dramatic Sell-Off Follows The Annountement That Novo Nordisk Would Cut Ist Full-Year 2025 Revenue and Profit Guidance for The Second Time This Year, Underscoring Mounting Growth Challenges in ITS Obesity and Diabetes Drug Franchis.
Danish Pharma Veteran Maziar Mike Doustdar Was Named The New Ceo and President, Effective August 7, Replace Lars Fruerd Jørgensen, Who Was Ousted in May.
The Leadership Transition Arrives as The Company Contends with Intelligying Competition From Eli Lilly’s Zepbound and Widespand Compounded “Knockoff”Versions of its Blockbuster Drugs Wegovy and Ozempic, particularly in the United States.
Novo now FORECASTS SALES GROWTH OF JUS 8–14%, DOWN FROM ITS PRIOR 13–21% GUIDANCE, WHILE OPERATING PROFIT GROWTH IS EXPECTED TO FALL TO 10–16% RANGE, BELOW THE FORMER OUTLOOK OF 16–24%.
The Muted Outlook for The Rest of 2025 Reflects Weaker-Than-Antaldated Demand For Wegovy in the Crucial US Obesity Market, Slower Ozempic Growth in Us Diabetes, and Delayed Expansion For Wegovy Internationally. ANALYSTS FLAGGED THE FORECAST REVIEW AS A SIGNAL THAT PROFIT ESTIMATES MAY FACE FURTHER DOWNWARD Pressure in the Coming Quarters.
Evite Robust Results Earlier in the Year-as 18% Rise in Sales and 29% Growth in Operating Profit for the First Half-Persistent Challenges In Supply, US Regulatory Hurdles, and A Surge of Generics Have Called Into Question Novo’s Outsized Lead in Weight-The Medicine Medicines.
At the peak of songs in June 2024, Novo Nordisk Was Europe’s Most Valuable Listed Company, But Today’s Plunge Starkly Illustrates The Risks Facing Even The Most Successful Health Health Leaders Sector.
Full Second-Quarter Earnings Are Scheduled To Be Released on August 6, With Global Investors Watching Closely for Signs of Stabilization-Ar Further Volatility-In This Embattled Pharma Heavyweight.
